Literature DB >> 26708047

Mouse models of DNA mismatch repair in cancer research.

Kyeryoung Lee1, Elena Tosti1, Winfried Edelmann2.   

Abstract

Germline mutations in DNA mismatch repair (MMR) genes are the cause of hereditary non-polyposis colorectal cancer/Lynch syndrome (HNPCC/LS) one of the most common cancer predisposition syndromes, and defects in MMR are also prevalent in sporadic colorectal cancers. In the past, the generation and analysis of mouse lines with knockout mutations in all of the known MMR genes has provided insight into how loss of individual MMR genes affects genome stability and contributes to cancer susceptibility. These studies also revealed essential functions for some of the MMR genes in B cell maturation and fertility. In this review, we will provide a brief overview of the cancer predisposition phenotypes of recently developed mouse models with targeted mutations in MutS and MutL homologs (Msh and Mlh, respectively) and their utility as preclinical models. The focus will be on mouse lines with conditional MMR mutations that have allowed more accurate modeling of human cancer syndromes in mice and that together with new technologies in gene targeting, hold great promise for the analysis of MMR-deficient intestinal tumors and other cancers which will drive the development of preventive and therapeutic treatment strategies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA mismatch repair; Hereditary non-polyposis colon cancer; Lynch syndrome; Mlh1; Mouse models; Msh2

Mesh:

Year:  2015        PMID: 26708047      PMCID: PMC4754788          DOI: 10.1016/j.dnarep.2015.11.015

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  61 in total

1.  Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background.

Authors:  Neil J Toft; Lucy J Curtis; Owen J Sansom; Andrea L Leitch; Andrew H Wyllie; Hein te Riele; Mark J Arends; Alan R Clarke
Journal:  Oncogene       Date:  2002-09-12       Impact factor: 9.867

Review 2.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

Review 3.  The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia.

Authors:  Basil Rigas
Journal:  Curr Opin Gastroenterol       Date:  2007-01       Impact factor: 3.287

4.  Mutational specificity of mice defective in the MTH1 and/or the MSH2 genes.

Authors:  Akinori Egashira; Kazumi Yamauchi; Kaoru Yoshiyama; Hisaya Kawate; Motoya Katsuki; Mutsuo Sekiguchi; Keizo Sugimachi; Hisaji Maki; Teruhisa Tsuzuki
Journal:  DNA Repair (Amst)       Date:  2002-11-03

5.  An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.

Authors:  Melanie H Kucherlapati; Kyeryoung Lee; Andrew A Nguyen; Alan B Clark; Harry Hou; Andrew Rosulek; Hua Li; Kan Yang; Kunhua Fan; Martin Lipkin; Roderick T Bronson; Linda Jelicks; Thomas A Kunkel; Raju Kucherlapati; Winfried Edelmann
Journal:  Gastroenterology       Date:  2009-11-18       Impact factor: 22.682

Review 6.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

7.  Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.

Authors:  Kamila Wojciechowicz; Erika Cantelli; Bastiaan Van Gerwen; Mirjam Plug; Anja Van Der Wal; Elly Delzenne-Goette; Ji-Ying Song; Sandra De Vries; Marleen Dekker; Hein Te Riele
Journal:  Gastroenterology       Date:  2014-07-31       Impact factor: 22.682

8.  Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells.

Authors:  Michael A McIlhatton; Jessica Tyler; Susan Burkholder; Josef Ruschoff; Basil Rigas; Levy Kopelovich; Richard Fishel
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.

Authors:  Marina Kovalenko; Ella Dragileva; Jason St Claire; Tammy Gillis; Jolene R Guide; Jaclyn New; Hualing Dong; Raju Kucherlapati; Melanie H Kucherlapati; Michelle E Ehrlich; Jong-Min Lee; Vanessa C Wheeler
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

10.  Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.

Authors:  Benedikt Kortüm; Christoph Campregher; Michaela Lang; Vineeta Khare; Matthias Pinter; Rayko Evstatiev; Gerald Schmid; Martina Mittlböck; Theresa Scharl; Melanie H Kucherlapati; Winfried Edelmann; Christoph Gasche
Journal:  Gut       Date:  2014-11-26       Impact factor: 23.059

View more
  14 in total

Review 1.  Eukaryotic Mismatch Repair in Relation to DNA Replication.

Authors:  Thomas A Kunkel; Dorothy A Erie
Journal:  Annu Rev Genet       Date:  2015       Impact factor: 16.830

Review 2.  Pathways and Mechanisms that Prevent Genome Instability in Saccharomyces cerevisiae.

Authors:  Christopher D Putnam; Richard D Kolodner
Journal:  Genetics       Date:  2017-07       Impact factor: 4.562

3.  Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin.

Authors:  Björn Hiller; Anja Hoppe; Rayk Behrendt; Axel Roers; Christa Haase; Christina Hiller; Nadja Schubert; Werner Müller; Martin A M Reijns; Andrew P Jackson; Thomas A Kunkel; Jörg Wenzel
Journal:  Cancer Res       Date:  2018-08-28       Impact factor: 12.701

Review 4.  Should mutant TP53 be targeted for cancer therapy?

Authors:  Andreas Strasser; Gemma L Kelly; Zilu Wang
Journal:  Cell Death Differ       Date:  2022-03-24       Impact factor: 12.067

5.  Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution.

Authors:  Mirjana Efremova; Dietmar Rieder; Victoria Klepsch; Pornpimol Charoentong; Francesca Finotello; Hubert Hackl; Natascha Hermann-Kleiter; Martin Löwer; Gottfried Baier; Anne Krogsdam; Zlatko Trajanoski
Journal:  Nat Commun       Date:  2018-01-02       Impact factor: 14.919

6.  Microsatellite Instability in Mouse Models of Colorectal Cancer.

Authors:  Nicola Currey; Joseph J Daniel; Dessislava N Mladenova; Jane E Dahlstrom; Maija R J Kohonen-Corish
Journal:  Can J Gastroenterol Hepatol       Date:  2018-03-01

7.  Loss of mismatch repair signaling impairs the WNT-bone morphogenetic protein crosstalk and the colonic homeostasis.

Authors:  Katrine Nørgaard; Carolin Müller; Nadja Christensen; María L Chiloeches; Cesilie L Madsen; Sabine S Nielsen; Tine E Thingholm; Antoaneta Belcheva
Journal:  J Mol Cell Biol       Date:  2020-07-03       Impact factor: 6.216

Review 8.  The Mutator Phenotype: Adapting Microbial Evolution to Cancer Biology.

Authors:  Federica Natali; Giulia Rancati
Journal:  Front Genet       Date:  2019-08-06       Impact factor: 4.599

9.  The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.

Authors:  Claudia Maletzki; Franziska Beyrich; Maja Hühns; Ernst Klar; Michael Linnebacher
Journal:  Oncotarget       Date:  2016-08-16

10.  Complex pattern of immune evasion in MSI colorectal cancer.

Authors:  Mine Ozcan; Jonas Janikovits; Magnus von Knebel Doeberitz; Matthias Kloor
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.